NYSE · Healthcare · Medical Devices · USA
Edwards Lifesciences Corp is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Edwards Lifesciences develops medical technologies for treating cardiovascular diseases, particularly structural heart conditions affecting heart valves. The company offers three main product groups: transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical heart valves, serving patients through direct sales forces and distributors globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Edwards Lifesciences Corp stock.
Overvalued: intrinsic value $42.35 per share, market price $87.22, margin of safety -105.9% (as of 2026-10-19).
Discounting its cash flows at 9.5% (average of 3 methods) values the shares at $42.35; the price of $87.22 is 106% above that value, and 75% of that value comes from beyond year five.
Leak Score: 42/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
38 more in this industry show a wider margin of safety.
EW is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.5% (average of 3 methods) values the shares at $42.35; the price of $87.22 is 106% above that value, and 75% of that value comes from beyond year five.
$42.35 per share (as of the 2026-10-19 close), against a market price of $87.22. That is a margin of safety of -105.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 46.4%. Yearly sales growth it has sustained: 11.5%.
42 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.